Patient must be fasting for 4 hours, verify dual antiplatelet therapy compliance, obtain informed consent, baseline ECG, complete blood count, and coagulation profile check.
Manual or device-assisted hemostasis at the puncture site, 2-4 hours of clinical observation in the recovery area, monitoring for hematoma or vascular complications, discharge with clear instructions on activity limitations and mandatory antiplatelet therapy compliance.
Comprehensive Clinical Guide: Percutaneous Coronary Intervention (PCI) with Bioresorbable Scaffolds (BRS)
1. Introduction and Overview
Percutaneous Coronary Intervention (PCI) has evolved significantly since the advent of balloon angioplasty. While metallic Drug-Eluting Stents (DES) have been the gold standard for decades, they present inherent long-term limitations, such as permanent metallic caging of the vessel, potential for late-stent thrombosis, and impaired vasomotion.
The Bioresorbable Scaffold (BRS) represents a paradigm shift in interventional cardiology. Designed to provide temporary mechanical support to the coronary artery during the healing phase of the vessel wall and then gradually dissolve, BRS aims to restore the vessel’s natural physiology. This guide provides an exhaustive clinical overview of the BRS technology, procedural nuances, and patient management protocols.
2. Technical Specifications and Mechanism of Action
Unlike traditional stainless steel or cobalt-chromium stents, BRS systems are constructed from biocompatible, biodegradable polymers—most commonly Poly-L-Lactide (PLLA).
The Life Cycle of a BRS
- Support Phase: The scaffold provides radial strength similar to metallic stents for the first 3–6 months to prevent acute recoil and remodeling.
- Resorption Phase: Through hydrolysis, the polymer chains are broken down. The scaffold gradually loses its structural integrity.
- Restoration Phase: The scaffold is fully metabolized into carbon dioxide and water, leaving the artery free of permanent foreign material.
Comparative Technical Matrix
| Feature | Metallic Drug-Eluting Stent (DES) | Bioresorbable Scaffold (BRS) |
|---|---|---|
| Material | Cobalt-Chromium / Platinum-Chromium | Poly-L-Lactide (PLLA) |
| Persistence | Permanent | Transient (12–36 months) |
| Vessel Vasomotion | Constrained | Restored post-resorption |
| Imaging Profile | Radiopaque (Artifacts) | Radiolucent (Allows IVUS/OCT clarity) |
| Long-term Risk | Late Stent Thrombosis | Scaffold Thrombosis (Early/Late) |
3. Clinical Indications and Usage
BRS is indicated for patients with symptomatic coronary artery disease (CAD) resulting from de novo native coronary artery lesions.
Ideal Patient/Lesion Selection
- Lesion Type: Simple, non-calcified, de novo lesions in vessels with a reference diameter of 2.5mm to 4.0mm.
- Anatomical Suitability: Patients with localized, discrete lesions rather than diffuse, heavily calcified, or tortuous anatomy.
- Patient Profile: Younger patients with a longer life expectancy who may benefit from the absence of permanent metal in the coronary tree.
Contraindications
- Vessel Size: Vessels < 2.5mm (risk of scaffold thrombosis).
- Lesion Morphology: Severe, circumferential calcification (prevents proper scaffold expansion).
- Anatomical Complexity: Highly tortuous vessels where delivery may cause vessel damage.
- Hypersensitivity: Known allergy to PLLA or the antiproliferative drug (e.g., Everolimus).
4. Pre-Operative Preparation
Success with BRS is highly dependent on rigorous lesion preparation. The "PSP" technique is the clinical standard:
- P - Pre-dilation: Use of a non-compliant balloon to ensure the lesion is adequately opened. The balloon-to-artery ratio should be 1:1.
- S - Sizing: Precise measurement of the vessel diameter via Intravascular Ultrasound (IVUS) or Optical Coherence Tomography (OCT) is mandatory. Do not "oversize" the scaffold.
- P - Post-dilation: Mandatory use of a non-compliant balloon at high pressure to ensure full apposition of the scaffold struts against the vessel wall.
5. The Procedure: Step-by-Step
- Access: Radial artery access is preferred to minimize vascular complications.
- Angiography: Initial diagnostic run to map the lesion.
- Lesion Preparation: Perform aggressive pre-dilation using non-compliant balloons.
- Deployment: Advance the BRS system through the guide catheter. Deploy at nominal pressure.
- Post-Dilation: Exchange for a high-pressure non-compliant balloon. Dilate at high pressure (16–20 atm) to ensure the scaffold is fully expanded.
- Imaging Verification: Use IVUS/OCT to confirm no malapposition, edge dissection, or underexpansion.
6. Post-Operative Recovery and Protocol
Post-procedural care is critical to prevent scaffold thrombosis.
- Dual Antiplatelet Therapy (DAPT): Strict adherence to DAPT (typically Aspirin + a P2Y12 inhibitor) for at least 12 months. Early cessation is a primary driver of scaffold thrombosis.
- Activity: Bed rest for 2–4 hours post-sheath removal. Gradual return to light activity within 48 hours.
- Follow-up: Clinical follow-up at 1, 6, and 12 months. Routine stress testing is recommended if the patient remains symptomatic.
7. Complications and Management
While BRS offers long-term benefits, it carries unique risks:
- Scaffold Thrombosis: Occurs if the scaffold is underexpanded or if DAPT is stopped prematurely. Requires emergent repeat angiography.
- Edge Dissection: Often caused by aggressive pre-dilation or mismatching. Requires a second device or prolonged balloon inflation.
- Malapposition: Incomplete contact between the scaffold and the vessel wall. Can be mitigated by mandatory post-dilation.
8. Alternative Treatments
- Drug-Eluting Stents (DES): The current benchmark for safety and efficacy. Preferred for complex, calcified, or small-vessel disease.
- Coronary Artery Bypass Grafting (CABG): Preferred for multi-vessel disease, left main disease, or diabetic patients with complex anatomy.
- Drug-Coated Balloons (DCB): Emerging technology for in-stent restenosis or small vessel disease that avoids the need for permanent implants.
9. Massive FAQ Section
Q1: How long does it take for a BRS to dissolve?
A: Typically, the scaffold begins to degrade at 6 months and is mostly resorbed into the vessel wall between 24 and 36 months.
Q2: Is BRS better than a metallic stent?
A: It is not necessarily "better" but offers a different long-term profile. It removes the "full metal jacket" effect, potentially allowing for future bypass surgery or interventions in the same segment.
Q3: Can I have an MRI after receiving a BRS?
A: Yes. Because the scaffold is made of polymer and eventually disappears, it is MRI safe/conditional.
Q4: What happens if the scaffold breaks?
A: Unlike metallic stents, a BRS is designed to be flexible. Minor structural discontinuities during the resorption process are normal and do not typically cause clinical issues if the vessel has healed.
Q5: Why is post-dilation so important?
A: BRS struts are thicker than metallic stents. Ensuring they are flush against the vessel wall (apposition) is the single most important step in preventing thrombus formation.
Q6: What is the risk of "Late Stent Thrombosis"?
A: While BRS reduces the risk of permanent metallic thrombosis, there is a risk of scaffold thrombosis during the resorption phase if DAPT is not maintained.
Q7: Is BRS suitable for diabetic patients?
A: Generally, BRS is used with caution in diabetic patients due to their tendency for complex, diffuse, and calcified lesions. Individual assessment is required.
Q8: What if I need another procedure later?
A: If the vessel is fully healed and the scaffold has resorbed, the anatomy is essentially "virgin," allowing for easier repeat interventions compared to an artery lined with permanent metal.
Q9: How do I know if my vessel is the right size?
A: Your interventional cardiologist will use IVUS or OCT imaging during the procedure to measure the exact diameter of your coronary artery.
Q10: Can I stop my blood thinners early?
A: Absolutely not. Premature discontinuation of DAPT is the highest risk factor for catastrophic scaffold thrombosis. Always consult your cardiologist before modifying your medication regimen.
10. Clinical Summary for Healthcare Providers
The implementation of Bioresorbable Scaffolds requires a disciplined, technique-driven approach. The "PSP" protocol is not optional; it is the fundamental requirement for procedural success. Clinicians must prioritize proper patient selection, avoiding the temptation to use BRS in highly calcified or extremely small vessels where metallic DES remain superior. When used in the correct anatomical context, BRS provides a sophisticated, physiological solution that respects the long-term integrity of the coronary vasculature.
Disclaimer: This document is intended for educational and clinical guidance purposes only. It does not replace the judgment of a qualified healthcare professional. All interventional procedures carry inherent risks; patients should discuss specific risks and benefits with their cardiology team.